$5.93 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$74.25 - $214.07The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$5.93 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+39.5%|
|Outstanding Shares||49.3 Million|
|Avg 30 Day Volume||410 Thousand|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
15,673 shares sold (16 transactions)
25,931 shares sold (11 transactions)
40,030 shares sold (13 transactions)
CEO: Emily Leproust
Industry: Research and Development in Biotechnology
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,740 shares of the businesss stock in a transaction that occurred on Thursday, October 21st. The shares were sold at an average price ...Dakota Financial News, 2 days ago
Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 300 shares of the firms stock in a transaction that occurred on Tuesday, October 19th. The stock was sold at an average price of $120.0...Transcript Daily, 7 days ago
Franklin Resources Inc. decreased its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 0.2% in the second quarter, Holdings Channel reports. The firm owned 134,542 shares of the companys stock aft...Dakota Financial News, 8 days ago